Publicaciones en las que colabora con Enrique Morales Ruiz (10)

2024

  1. Detection of binucleated nephrin-marked podocytes by flow cytometry in the urine of patients with obesity

    Journal of Nephrology

  2. Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia

    Kidney International Reports, Vol. 9, Núm. 5, pp. 1419-1428

2022

  1. Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 37, Núm. 6, pp. 1125-1131

2021

  1. Renoprotective role of bariatric surgery in patients with established chronic kidney disease

    Clinical Kidney Journal, Vol. 14, Núm. 9, pp. 2037-2046

  2. The Role of Vascular Lesions in Diabetes Across a Spectrum of Clinical Kidney Disease

    Kidney International Reports, Vol. 6, Núm. 9, pp. 2392-2403

  3. Validation of a Histologic Scoring Index for C3 Glomerulopathy

    American Journal of Kidney Diseases, Vol. 77, Núm. 5, pp. 684-695.e1

2020

  1. Erratum: SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (Nephrology Dialysis Transplantation (2019) (gfy407) DOI: 10.1093/NDT/gfy407)

    Nephrology Dialysis Transplantation

  2. Erratum: SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (Nephrology Dialysis Transplantation (2019) 34:2 (208–230) DOI:10.1093/ndt/gfy407)

    Nephrology Dialysis Transplantation

  3. The estimation of GFR and the adjustment for BSA in overweight and obesity: a dreadful combination of two errors

    International Journal of Obesity, Vol. 44, Núm. 5, pp. 1129-1140

2019

  1. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

    Nephrology Dialysis Transplantation, Vol. 34, Núm. 2, pp. 208-230